1. Home
  2. IPSC vs IOBT Comparison

IPSC vs IOBT Comparison

Compare IPSC & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

HOLD

Current Price

$1.26

Market Cap

58.3M

Sector

Health Care

ML Signal

HOLD

Logo IO Biotech Inc.

IOBT

IO Biotech Inc.

HOLD

Current Price

$0.63

Market Cap

57.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPSC
IOBT
Founded
2019
2014
Country
United States
Denmark
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.3M
57.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
IPSC
IOBT
Price
$1.26
$0.63
Analyst Decision
Strong Buy
Buy
Analyst Count
6
4
Target Price
$3.00
$3.50
AVG Volume (30 Days)
1.5M
695.2K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$113,337,000.00
N/A
Revenue This Year
$1,590.09
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4122.69
N/A
52 Week Low
$0.34
$0.32
52 Week High
$1.19
$2.79

Technical Indicators

Market Signals
Indicator
IPSC
IOBT
Relative Strength Index (RSI) 76.36 44.08
Support Level $0.90 $0.60
Resistance Level $1.05 $0.70
Average True Range (ATR) 0.14 0.07
MACD 0.02 -0.00
Stochastic Oscillator 96.15 40.40

Price Performance

Historical Comparison
IPSC
IOBT

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

About IOBT IO Biotech Inc.

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Share on Social Networks: